A new vaccines drug substance facility and R&D pilot plant, completed by the end of 2028, will create over 200 new jobs.

The site is slated to help produce freeze-dried vaccines such as the company's respiratory syncytial virus launch Arexvy and its shingles vaccine Shingrix. GSK pumps £200M+ into UK manufacturing ...

GSK expects to begin construction immediately on the project, which includes a new 270,000-square-foot-facility for research and manufacturing ... produced at other sites and employs 380 people.

Additionally, GSK will establish a new vaccines drug substance facility at the site, dedicated to manufacturing products based on the company’s novel MAPS technology, subsequent to future ...

Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...

We hope today is manageable and productive. Best of luck, and keep in touch. … GSK plans to depart the biotechnology industry ...

Then his mother, Alia Hayes, got some bad news. The manufacturer, GSK, was going to stop manufacturing the brand-name ...

GSK's major growth drivers, Shingrix and Arexvy, along with recent legal progress, make its current undervaluation ...

GSK has licensed a small molecule for Parkinson's and is teaming up on additional targets for the disease and another ...

Just like our memory and reflexes, the ageing of our immune system can not only cause it to forget how to react to certain ...

Following outlays for sites in the UK and Belgium earlier this year, GSK is planning to invest up to $800m in the US to double the size and capacity of its site in Marietta, Pennsylvania.